ArticleFrontiers in endocrinology2026
Albuminuria, but not eGFR, tracks diabetic retinopathy severity and retinal ischemia: population-based discovery, clinical replication, and OCTA evidence.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We investigated whether albuminuria is more consistently associated with diabetic retinopathy (DR) severity than estimated glomerular filtration rate (eGFR) and whether it corresponds to an ischemic retinal phenotype on optical coherence tomography angiography (OCTA). Methods: This two-part cross-sectional study first analyzed 949 adults with diabetes from the National Health and Nutrition Examination Survey (NHANES) to evaluate the associations of albumin-to-creatinine ratio (ACR) and eGFR with the DR outcomes. An independent single-center cohort of 168 adults with type 2 diabetes, including a nested 134-participant OCTA subset, was then used to examine the associations of urine ACR (UACR) and eGFR with the clinical DR endpoints and retinal perfusion metrics. Results: In the NHANES, each doubling of ACR was independently associated with higher odds of AnyDR and SevereDR, with stronger association for SevereDR (odds ratio, OR = 1.30), whereas eGFR showed no independent association. In the clinical cohort, each doubling of UACR was associated with higher odds of moderate-or-worse DR and vision-threatening diabetic retinopathy (VTDR) (OR = 2.86 and 2.70, respectively), while eGFR remained non-significant. In the OCTA subset, a higher UACR was associated with greater widefield non-perfusion and lower macular perfusion density, whereas eGFR was not associated with either OCTA endpoint. Conclusions: Across the studied cohorts, albuminuria was consistently associated with more severe DR and an ischemic OCTA phenotype, whereas eGFR did not show an independent association within the observed kidney function range. Spot urine ACR testing may serve as a practical biomarker for stratifying retinal microvascular ischemia risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.